QTXB Stock Overview
QuantRx Biomedical Corporation engages in the development and commercialization of patented miniform pads (PADs) and PAD based over-the-counter products in the United States.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
QuantRx Biomedical Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.004 |
52 Week High | US$0.01 |
52 Week Low | US$0.000001 |
Beta | -2.16 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | -46.67% |
3 Year Change | -75.00% |
5 Year Change | -16.67% |
Change since IPO | -99.85% |
Recent News & Updates
Recent updates
Shareholder Returns
QTXB | US Medical Equipment | US Market | |
---|---|---|---|
7D | 0% | 2.2% | 0.4% |
1Y | -46.7% | 13.3% | 28.8% |
Return vs Industry: QTXB underperformed the US Medical Equipment industry which returned 12% over the past year.
Return vs Market: QTXB underperformed the US Market which returned 29.5% over the past year.
Price Volatility
QTXB volatility | |
---|---|
QTXB Average Weekly Movement | n/a |
Medical Equipment Industry Average Movement | 7.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: QTXB's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine QTXB's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1986 | n/a | Shalom Hirschman | https://www.quantrx.com/index.htm |
QuantRx Biomedical Corporation engages in the development and commercialization of patented miniform pads (PADs) and PAD based over-the-counter products in the United States. It is also developing genomic diagnostics for the laboratory market based on its lateral flow patents, including RapidSense technology, a one-step lateral flow test. The company’s PAD products are used for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses, and other medical needs.
QuantRx Biomedical Corporation Fundamentals Summary
QTXB fundamental statistics | |
---|---|
Market cap | US$314.79k |
Earnings (TTM) | -US$260.51k |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs QTXB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
QTXB income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$260.51k |
Earnings | -US$260.51k |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0033 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -53.5% |
How did QTXB perform over the long term?
See historical performance and comparison